Consistently, in pancreatic cancer cells KRAS has been shown to increase GLI1 activity via MEK1/2-ERK1/2, and KRAS-mediated activation of GLI1 is suppressed with UO126, through decrease of GLI1 protein stability [89]. The gene discussed is GLI1; the disease is pancreatic neoplasm.